Diligence memo · auto-generated · as of July 2, 2026
Caliper Life Sciences Inc
Caliper Life Sciences Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Caliper Life Sciences Inc operates in Biotechnology, based in Hopkinton.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Caliper Life Sciences Inc has raised $11M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $11M on 2010-12-17.
Most recent recorded round closed around 2010-12-17.
Valuation (modeled)modeled
Provath models Caliper Life Sciences Inc at approximately $390M (range $12M–$2.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.95× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 15.5 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 58% of Biotechnology peers (4293 compared).
Modeled value ranks above 80% of those peers.
Closest niche peers: Tobira Therapeutics, Inc., Neoprobe Corp, Akebia Therapeutics, Inc., Adimab, LLC, Elevation Pharmaceuticals Inc.
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.